Literature DB >> 16788815

Management of non-complicated BPH: proposition of a renewed decision tree.

Francois Desgrandchamps1, Alexandre de la Taille, Abdel-Rahmène Azzouzi, Marc Fourmarier, Olivier Haillot, Bertrand Lukacs, Christian Saussine.   

Abstract

Nowadays the management of benign prostatic hypertrophia (BPH) is undergoing striking changes. The standard medical treatments are represented by three families which are the phytotherapy, the alpha-blockers and the 5-alpha-reductase inhibitors. These treatments were deemed as symptomatic and used only as monotherapy. Recent numerous studies bring new assessments on BPH: the medical treatment is able to modify the natural history of BPH especially by reducing the risk of acute urinary retention. Furthermore the association of two different therapeutic classes seems to be more efficient than the use of a monotherapy in some cases. Similarly the place of two instrumental techniques, the thermotherapy by microwaves or by radiofrequencies, previously proposed as alternatives to the surgical treatment seems to find their way rather as alternatives to the medical treatment. These different elements allow building a renewed decision tree which decisions are shared with the patient at each stage. This decision tree of the management of patients having non-complicated BPH symptoms must include initial clinical characteristics of the patient and its disease and the evolution under treatment which has not been yet considered in the international recommendations. It also considers the possibilities of associations with other therapeutic classes.

Entities:  

Mesh:

Year:  2006        PMID: 16788815     DOI: 10.1007/s00345-006-0096-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.

Authors:  Alexandre R Zlotta; Xenofon Giannakopoulos; Odd Maehlum; Tonnes Ostrem; Claude C Schulman
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

2.  Natural history of prostatism: urinary flow rates in a community-based study.

Authors:  C J Girman; L A Panser; C G Chute; J E Oesterling; D M Barrett; C C Chen; H M Arrighi; H A Guess; M M Lieber
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

3.  Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging.

Authors:  H M Arrighi; E J Metter; H A Guess; J L Fozzard
Journal:  Urology       Date:  1991       Impact factor: 2.649

4.  Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia.

Authors:  Andrew H Tan; Linda Nott; W Robert Hardie; Joseph L Chin; John D Denstedt; Hassan Razvi
Journal:  J Endourol       Date:  2005-12       Impact factor: 2.942

Review 5.  Dosage and duration of medication for men with lower urinary tract symptoms: two questions without definitive answers.

Authors:  François Desgrandchamps; Pierre Mongiat-Artus
Journal:  Curr Opin Urol       Date:  2006-01       Impact factor: 2.309

6.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

Authors:  C G Roehrborn; P Boyle; D Bergner; T Gray; M Gittelman; T Shown; A Melman; R B Bracken; R deVere White; A Taylor; D Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

7.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

8.  EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

Authors:  Stephan Madersbacher; Gerasimos Alivizatos; Jorgen Nordling; Carlos Rioja Sanz; Mark Emberton; Jean J M C H de la Rosette
Journal:  Eur Urol       Date:  2004-11       Impact factor: 20.096

9.  Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.

Authors:  K M C Verhamme; J P Dieleman; G S Bleumink; J L H R Bosch; B H Ch Stricker; M C J M Sturkenboom
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

Review 10.  Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS.

Authors:  François Desgrandchamps
Journal:  Curr Opin Urol       Date:  2004-01       Impact factor: 2.309

View more
  3 in total

1.  Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Richard-Olivier Fourcade; François Lacoin; Morgan Rouprêt; Alain Slama; Camille Le Fur; Emilie Michel; Axel Sitbon; François-Emery Cotté
Journal:  World J Urol       Date:  2011-09-03       Impact factor: 4.226

2.  A Classification Tree Model with Optical Coherence Tomography Angiography Variables to Screen Early-Stage Diabetic Retinopathy in Diabetic Patients.

Authors:  Hongyan Yao; Shanjun Wu; Zongyi Zhan; Zijing Li
Journal:  J Ophthalmol       Date:  2022-02-15       Impact factor: 1.909

3.  A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.

Authors:  Emeka I Udeh; Chimaobi G Ofoha; David A Adewole; Ikenna I Nnabugwu
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.